ImmunityBio
ImmunityBio develops immunotherapy products to enhance the immune system's ability to combat cancer and infectious diseases, offering tailored treatments and conducting extensive clinical trials.
ImmunityBio Services
ImmunityBio develops immunotherapy products focused on enhancing the immune system to combat cancer and infectious diseases. The company offers a range of investigational treatments tailored to meet individual patient needs, using advanced immunological strategies. ImmunityBio's services also encompass the provision of NK-92® cells for non-clinical research applications via Brink Biologics' Neukopanel® Licensing Program.
ImmunityBio Product Line
ImmunityBio's product offerings include ANKTIVA®, a first-in-class immunotherapy approved by the FDA for the treatment of non-muscle invasive bladder cancer (NMIBC). The company employs a 'triangle offense' strategy designed to achieve durable and comprehensive responses against cancer and infectious diseases. Additionally, ImmunityBio manufactures over three trillion cells and has multiple FDA-authorized Investigational New Drug (IND) applications for its natural killer (NK) cells.
ImmunityBio Research and Clinical Trials
ImmunityBio conducts clinical trials across a variety of tumor types, using platforms that address the entire immune system. One prominent collaboration is with the National Cancer Institute, aimed at preventing Lynch syndrome-related cancers. The company's comprehensive research efforts are geared towards generating data that could lead to durable responses in both cancer and infectious diseases.
ImmunityBio Financial and Manufacturing Capabilities
ImmunityBio has secured $300 million in non-dilutive capital to support the commercialization of its products and the expansion of its pipeline. In terms of manufacturing, the company has completed Good Manufacturing Practice (GMP) Drug Substance Manufacturing, sufficient to produce 170,000 doses of ANKTIVA®.